Urinary and Circulating Tumor DNA in Muscle-Invasive Bladder Cancer: NIAGARA Data
Project Oncology®Urinary and Circulating Tumor DNA in Muscle-Invasive Bladder Cancer: NIAGARA Data
Charles Turck, PharmD, BCPS, BCCCP
Petros Grivas, MD, PhD
ctDNA-Guided Adjuvant Atezolizumab in MIBC: IMvigor011 Insights
Project Oncology®ctDNA-Guided Adjuvant Atezolizumab in MIBC: IMvigor011 Insights
Charles Turck, PharmD, BCPS, BCCCP
Guru P. Sonpavde, MD
Redefining First-Line Therapy in mCSPC: Applying Evidence in Practice
Project Oncology®Redefining First-Line Therapy in mCSPC: Applying Evidence in Practice
Brian P. McDonough, MD, FAAFP
William Oh, MD
ctDNA-Guided Bladder Preservation in Muscle-Invasive Bladder Cancer
Project Oncology®ctDNA-Guided Bladder Preservation in Muscle-Invasive Bladder Cancer
Charles Turck, PharmD, BCPS, BCCCP
Pooja Ghatalia, MD
ctDNA-Guided Immunotherapy Shows Survival Benefit in MIBC: IMvigor011 Results
Project Oncology®ctDNA-Guided Immunotherapy Shows Survival Benefit in MIBC: IMvigor011 Results
Charles Turck, PharmD, BCPS, BCCCP
Andrea Necchi, MD
Adjuvant Nivolumab in High-Risk Muscle Invasive Urothelial Carcinoma: 5-Year Data
Project Oncology®Adjuvant Nivolumab in High-Risk Muscle Invasive Urothelial Carcinoma: 5-Year Data
Brian P. McDonough, MD, FAAFP
Matthew Galsky, MD
- advertisement
Shifting the Script: Personalizing Overactive Bladder Treatment in Complex Patients
CME/CEShifting the Script: Personalizing Overactive Bladder Treatment in Complex Patients
David Staskin, MD
Matt T. Rosenberg, MD
Kennedy Koebbe, MSN, RN
Expert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer
CME/CEExpert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer
Neal Shore, MD, FACS
Sarah Psutka, MD, MS
Patient-Centric ADT Intensification in Hormone-Sensitive Prostate Cancer: Balancing Efficacy, Safety, Quality of Life, and Survival
CME/CE Broadcast ReplayPatient-Centric ADT Intensification in Hormone-Sensitive Prostate Cancer: Balancing Efficacy, Safety, Quality of Life, and Survival
Mary-Ellen Taplin, MD
Ignacio Duran, MD
Wenxin Xu, MD
Sandy Srinivas, MD
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
MinuteCE®Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
Ignacio Duran, MD
Wenxin Xu, MD
Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
MinuteCE®Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
Ignacio Duran, MD
Sandy Srinivas, MD
- advertisement